-

Fresenius Kabi Awarded Technology Breakthrough Agreement with Premier, Inc. for the Ivenix Infusion System

original The Ivenix Infusion System from Fresenius Kabi was awarded a Breakthrough Technology group purchasing agreement with Premier, Inc. (Photo: Business Wire)

The Ivenix Infusion System from Fresenius Kabi was awarded a Breakthrough Technology group purchasing agreement with Premier, Inc. (Photo: Business Wire)

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today it has been awarded a Breakthrough Technology group purchasing agreement with Premier, Inc. Effective May 1, 2023, the new agreement allows Premier members, at their discretion, to benefit from special pricing and terms pre-negotiated by Premier for the Ivenix Infusion System from Fresenius Kabi.

“We deeply appreciate this vote of confidence in the Ivenix Infusion System and look forward to working with Premier members,” said Christian Hauer, executive board member and president, Fresenius Kabi MedTech. “Health systems and their nursing teams face many day-to-day challenges associated with infusion therapy. The Ivenix Infusion System is designed to improve the simplicity, intelligence and reliability of infusion pumps. We’re pleased Premier chose to make our smart infusion system available to its members.”

The Ivenix Infusion System is designed to overcome deficiencies in legacy pumps. The Ivenix patented pumping technology delivers critical medications with flow that is measured and controlled to help optimize safety. The pump operates unaffected by external conditions such as bag height, back pressure, and fluid viscosity to deliver accurate medication delivery, and it protects patients from uncontrolled flow.

The Ivenix Large-Volume Pump includes a large, smartphone-like touchscreen that allows clinicians to auto-program, review, and accept medication orders on the pump. The built-in integration engine within the Ivenix Infusion System supports secure interoperability with leading electronic medical records (EMR) systems. The Ivenix system from Fresenius Kabi also offers valuable tools to automate testing, reducing the implementation timeline and the resources needed to synchronize the drug library with the EMR formulary.

The Ivenix platform also facilitates enterprise-wide, centralized management of the entire pump fleet. This device command center allows for comprehensive oversight of the infusion pump fleet from device utilization to location awareness, proactive maintenance, user management, and remote software and security updates—without wasting valuable time hunting and gathering devices.

Premier, Inc. is a leading healthcare improvement company, uniting an alliance of more than 4,400 U.S. hospitals and health systems and approximately 250,000 other providers and organizations to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost.

About Fresenius Kabi

Fresenius Kabi (www.fresenius-kabi.com/us) is a global healthcare company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition. The company’s products and services are used to help care for patients with critical and chronic conditions. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. To learn about U.S. career opportunities at Fresenius Kabi, visit www.fresenius-kabi.com/us/join-us and follow us on LinkedIn.

Contacts

Matt Kuhn (847) 220-3033
matt.kuhn@fresenius-kabi.com

Industry:

Fresenius Kabi

Release Versions
English
Hashtags
#FreseniusKabi

Contacts

Matt Kuhn (847) 220-3033
matt.kuhn@fresenius-kabi.com

Social Media Profiles
Fresenius Kabi USA
Fresenius Kabi USA on YouTube
More News From Fresenius Kabi

Fresenius Kabi Issues Nationwide Recall of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials Due to Presence of Glass Particles

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of the Fresenius Group, is recalling one lot of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (20 mg/mL)20 mL vials to the user level. An internal investigation at the firm found the product to contain glass particles. Risk Statement: The administration of an injectable product containing glass particulates may cause local irritation, pain, or swelling at the infusion site, as well as inflammation of the veins. More se...

Fresenius Kabi Issues Voluntary Nationwide Recall of One Lot of Morphine Sulfate Injection, USP in a Simplist® Prefilled Syringe Due to Labeling Mix-up

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of the Fresenius Group, is voluntarily recalling one lot of Morphine Sulfate Injection USP, Simplist® 2 mg/1 mL due to a label mix-up. The MicroVault labeled as Morphine 2 mg/1 mL, may contain a Prefilled Syringe of Dilaudid 0.5 mg/0.5 mL. This recall is being conducted to the user level. Use of a MicroVault labeled as Morphine Sulfate Injection 2 mg/mL containing a prefilled syringe of Dilaudid (hydromorphone HCl) 0.5 mg/...

Fresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. Market

BAD HOMBURG, Germany--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, announced today that the U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan®* (rituximab).1 Under an exclusive commercialization agreement, Fresenius Kabi holds exclusive rights to commercialize the biosimilar in the United States. The product was developed, manufactured, and submitted for approval by Dr. Reddy's...
Back to Newsroom